Capricor's Review Extension, Myocorzo Patent Battle, and Other Key Biopharma Events
DeramioCel: FDA Extends Review, Focusing on Upper Limb Function
Capricor Therapeutics (CAPR) saw its stock price surge by over 60% after the FDA agreed to review a modification to the Biologics License Application (BLA) for deramiocel (CAP-1002), including 24-month upper limb function data. This allogeneic, cardiac-derived mesenchymal cell therapy completed Phase 3 HOPE-3 trial, but the advisory committee voted 9 to 3 against its efficacy on July 29, 2026. The Prescription Drug User Fee Act (PDUFA) date of August 22 is expected to be extended due to the submission of the amendment, and focusing the review on upper limb function may open a regulatory pathway, although statistical analysis debates remain.
Myocorzo vs. Camzyos: Patent Dispute Between Approved Products
Cytokinetics (CYTK) filed a declaratory judgment action against Bristol Myers Squibb (BMY) and its subsidiary MyoKardia, seeking to invalidate U.S. Patent No. 12,616,697. This patent covers the administration of a cardiac myosin inhibitor after reducing or discontinuing beta-blockers, directly impacting the use of Myocorzo (aficamten), which was approved by the FDA in December 2025. Camzyos (mavacamten), a competing drug in the same class, was approved by the FDA on April 28, 2022, and generated $602 million in sales in 2024, making this dispute commercially significant.
Lyme Disease Vaccine Enters European Regulatory Review
Pfizer (PFE) and Valneva (VALN)'s PF-07307405 (LB6V, formerly VLA15) has officially entered the review phase after the European Medicines Agency (EMA) accepted the marketing authorization application. This Phase 3, hexavalent vaccine targets Borrelia outer membrane protein A (OspA) serotypes 1-6, and demonstrated over 70% efficacy in individuals aged 5 years and older in the VALOR trial. With approximately 476,000 Lyme disease diagnoses and treatments annually in the United States and about 132,000 reported cases in Europe, the lack of an approved human vaccine makes this a valuable first-to-market opportunity.
Indupro Transitions Dual-Target ADC to Clinical Trials
Indupro Therapeutics secured $77 million in Series B funding and initiated the Phase 1 trial of IDP-001. IDP-001 is a dual-specific antibody-drug conjugate (ADC) that recognizes both epidermal growth factor receptor (EGFR) and a proprietary tumor-associated antigen (TAPA-E1), delivering monomethyl auristatin E (MMAE). Unlike EGFR inhibitors such as cetuximab and osimertinib, IDP-001 leverages the proximity of the two targets to potentially reduce EGFR toxicity in normal tissues, and initial safety and pharmacokinetic assessments will focus on this aspect.
Rusfertide Rights Monetized and Veppanu Launched
Zealand Pharma (ZEAL) sold the milestone and royalty rights for rusfertide, a hepcidin mimetic for polycythemia vera, to Royalty Pharma (RPRX) for up to $100 million, with an upfront payment of $50 million. Rusfertide has completed Phase 3 trials, and Takeda Pharmaceutical (TAK) will handle global development and commercialization. Rigel Pharmaceuticals (RIGL) launched Veppanu (vepdegestrant), an ESR1-targeted oral protein degrader approved by the FDA on May 1, 2026, at a price of $29,400 per month, and finalized a deal with Arvinas (ARVN) and Pfizer for $70 million upfront and up to $320 million in milestone payments.
The extension of the deramiocel review delays the immediate risk of rejection, but the 9-to-3 negative advisory committee vote and regulatory uncertainties surrounding the revised 24-month analysis remain key value drivers for CAPR. Myocorzo, in the approval and commercialization phase, faces competition from Camzyos, which generated $602 million in sales in 2024, making the patent ruling crucial for CYTK's prescription growth and market share in the HCM space. PF-07307405, a Phase 3 candidate targeting approximately 476,000 annual diagnoses and treatments in the U.S. and 132,000 reported cases in Europe, offers a first-in-class opportunity as a human Lyme disease vaccine. The Phase 1 trial of IDP-001 will assess whether the dual-target EGFR ADC can reduce toxicity in normal tissues, and the $77 million in funding supports early clinical operations. The monetization of rusfertide rights and the $29,400 launch price of Veppanu provide benchmarks for evaluating the commercial potential of approved PROTACs and the value of non-core assets, respectively.
Source: BioPharma Dive (rss)